TY  - GEN
AU  - Lin,Li
AU  - Xu,Jian-ming
AU  - Wang,Yan
AU  - Ge,Fei-jiao
AU  - Liu,Lie-jun
AU  - Zhao,Chuan-hua
AU  - Li,Shan-shan
AU  - Liu,Jian-zhi
AU  - Li,Zhi-qiang
TI  - [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer]
SN  - 0253-3766
PY  - 2011///1202
KW  - Adenocarcinoma
KW  - blood
KW  - Adenocarcinoma, Mucinous
KW  - Adult
KW  - Aged
KW  - Angiogenesis Inhibitors
KW  - adverse effects
KW  - Antibodies, Monoclonal, Humanized
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - CA-19-9 Antigen
KW  - Camptothecin
KW  - administration & dosage
KW  - Carcinoembryonic Antigen
KW  - Colonic Neoplasms
KW  - Diarrhea
KW  - chemically induced
KW  - Disease-Free Survival
KW  - Female
KW  - Fluorouracil
KW  - Follow-Up Studies
KW  - Humans
KW  - Hypertension
KW  - Irinotecan
KW  - Leucovorin
KW  - therapeutic use
KW  - Male
KW  - Middle Aged
KW  - Neutropenia
KW  - Rectal Neoplasms
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Survival Rate
KW  - Young Adult
N1  - Publication Type: Clinical Trial; Journal Article
ER  -